SCHEMBL21789124

SCHEMBL21789124

CCOC(=O)C1(NCc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.47
PPARG P37231 2/20 0.47
KCNQ2 O43526 3/20 0.46
KCNQ3 O43525 2/20 0.46
NPSR1 Q6W5P4 1/20 0.43
LSS P48449 1/20 0.43
KCNQ4 P56696 1/20 0.43
KCNQ5 Q9NR82 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MTOR P42345 1/20 0.41
THRB P10828 1/20 0.40
P2RX7 Q99572 1/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
HSP90AA1 P07900 1/20 0.39
CRHBP P24387 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16838991 0.91 SSTR3 (0.44) EPHX2PPARGKCNQ2KCNQ3NPSR1
SCHEMBL21777316 0.89 EPHX2 (0.45) EPHX2PPARGKCNQ2KCNQ3NPSR1
SCHEMBL21789094 0.88 PPARG (0.44) EPHX2PPARGKCNQ2KCNQ3NPSR1
SCHEMBL21777929 0.86 EPHX2 (0.43) EPHX2PPARGKCNQ2KCNQ3NPSR1
SCHEMBL29116612 0.84 PPARG (0.41) EPHX2PPARGKCNQ2KCNQ3NPSR1
SCHEMBL1980329 0.82 POLB (0.49) EPHX2NPSR1ALDH1A1POLBGAA
SCHEMBL21777896 0.82 MAPT (0.46) EPHX2PPARGKCNQ2KCNQ3NPSR1
SCHEMBL16839832 0.80 PPARG (0.46) EPHX2PPARGKCNQ2KCNQ3NPSR1
SCHEMBL16839837 0.80 KCNQ2 (0.47) EPHX2PPARGKCNQ2KCNQ3NPSR1
SCHEMBL16839875 0.79 EPHX2 (0.41) EPHX2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276976-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-09-04 US disclosed
US-12275741-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-04-15 US disclosed
US-20240368172-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2024-11-07 US disclosed
US-11952381-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-04-09 US disclosed
US-20230090256-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-03-23 US disclosed
US-11414424-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-08-16 US disclosed
US-11414424-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-08-16 US disclosed
CN-112867539-A Cardiac muscle segment inhibitor 赛特凯恩蒂克公司 2021-05-28 CN disclosed
US-20200109148-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2020-04-09 US disclosed
US-20200109148-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2020-04-09 US disclosed
WO-2020047447-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. (US) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414424-B2 Cardiac sarcomere inhibitors TNNI3, MYLK2, TNNT2 EPHX2 4645/4885PPARG 4523/4885KCNQ2 1104/4885
US-20200109148-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 EPHX2 4645/4885PPARG 4523/4885KCNQ2 1104/4885
US-20230090256-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 EPHX2 4645/4885PPARG 4523/4885KCNQ2 1104/4885
US-12275741-B2 Cardiac sarcomere inhibitors TNNI3, MYLK2, TNNT2 EPHX2 4645/4885PPARG 4523/4885KCNQ2 1104/4885
US-20240368172-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 EPHX2 4645/4885PPARG 4523/4885KCNQ2 1104/4885
US-20250276976-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 EPHX2 4645/4885PPARG 4523/4885KCNQ2 1104/4885
US-11952381-B2 Cardiac sarcomere inhibitors TNNI3, MYLK2, TNNT2 EPHX2 4645/4885PPARG 4523/4885KCNQ2 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.